Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

HOWL

Werewolf Therapeutics (HOWL)

Werewolf Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:HOWL
DateTimeSourceHeadlineSymbolCompany
14/01/202500:00GlobeNewswire Inc.Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic OutlookNASDAQ:HOWLWerewolf Therapeutics Inc
07/01/202509:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOWLWerewolf Therapeutics Inc
07/01/202509:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOWLWerewolf Therapeutics Inc
07/01/202509:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOWLWerewolf Therapeutics Inc
21/11/202400:00GlobeNewswire Inc.Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare ConferenceNASDAQ:HOWLWerewolf Therapeutics Inc
08/11/202401:09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HOWLWerewolf Therapeutics Inc
08/11/202401:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOWLWerewolf Therapeutics Inc
08/11/202401:02GlobeNewswire Inc.Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
08/11/202401:00GlobeNewswire Inc.Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:HOWLWerewolf Therapeutics Inc
31/10/202423:00GlobeNewswire Inc.Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINEâ„¢ Molecule for Inflammatory DiseasesNASDAQ:HOWLWerewolf Therapeutics Inc
04/10/202423:00GlobeNewswire Inc.Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
03/09/202422:00GlobeNewswire Inc.Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:HOWLWerewolf Therapeutics Inc
08/08/202421:21Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:HOWLWerewolf Therapeutics Inc
08/08/202421:12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HOWLWerewolf Therapeutics Inc
08/08/202421:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOWLWerewolf Therapeutics Inc
08/08/202421:05GlobeNewswire Inc.Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:HOWLWerewolf Therapeutics Inc
25/06/202421:00GlobeNewswire Inc.Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomaNASDAQ:HOWLWerewolf Therapeutics Inc
03/06/202421:56Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOWLWerewolf Therapeutics Inc
01/06/202423:00GlobeNewswire Inc.Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid TumorsNASDAQ:HOWLWerewolf Therapeutics Inc
30/05/202422:00GlobeNewswire Inc.Werewolf Therapeutics to Participate at the Jefferies Global Healthcare ConferenceNASDAQ:HOWLWerewolf Therapeutics Inc
29/05/202406:27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOWLWerewolf Therapeutics Inc
25/05/202409:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOWLWerewolf Therapeutics Inc
25/05/202409:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOWLWerewolf Therapeutics Inc
25/05/202409:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOWLWerewolf Therapeutics Inc
25/05/202409:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOWLWerewolf Therapeutics Inc
24/05/202407:00GlobeNewswire Inc.Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
03/05/202421:00GlobeNewswire Inc.Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:HOWLWerewolf Therapeutics Inc
25/04/202400:05GlobeNewswire Inc.Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
23/04/202422:00GlobeNewswire Inc.Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
06/04/202407:30GlobeNewswire Inc.Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:HOWL